APOE and nonpapillary renal cell carcinoma: Therfore, targeting the APOE+ macrophage population and their associated signaling pathways could represent a promising therapeutic strategy to overcome immunotherapy resistance in ccRCC, potentially improving clinical outcomes for patients.